Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

This study has been terminated.
Sponsor:
Collaborators:
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier:
NCT00720629
First received: July 21, 2008
Last updated: July 10, 2014
Last verified: April 2014
  Purpose

The purpose of this study was to test whether a new drug named visilizumab would decrease the severity of graft-versus-host disease in patients treated with a mismatched donor. Investigators planned to use visilizumab in combination with tacrolimus and methotrexate as the "study treatment".


Condition Intervention Phase
Graft Versus Host Disease
Drug: Visilizumab
Drug: Tacrolimus
Drug: Methotrexate
Drug: Antithymocyte globulin (ATG)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Phase II Study of Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Resource links provided by NLM:


Further study details as provided by H. Lee Moffitt Cancer Center and Research Institute:

Primary Outcome Measures:
  • Number of Participants With Grade II-IV Acute Graft-versus-Host Disease (GVHD) Score at 100 Days [ Time Frame: 100 days ] [ Designated as safety issue: Yes ]

    Cumulative Incidence of Grade II-IV Acute GVHD Score at 100 Days. Investigators had planned to assess whether the grade of acute GVHD was decreased by visilizumab in combination with tacrolimus/methotrexate compared to standard treatment with thymoglobulin/tacrolimus/methotrexate after transplantation from unrelated mismatched donors, from day of transplant up to one year. Study was closed during the first treatment stage and did not proceed to the second stage treatment comparison to ATG in combination with tacrolimus/methotrexate as originally planned.

    Overall GVHD Grade: From Filipovich AH, Weisdorf D, Pavletic S, etal: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biology of Blood and Marrow Transplantation 11:945-955 (2005). Grade I: Skin Stage 1-2, Liver Stage 0, Gut State 0; Grade II: Skin Stage 3 or, Liver Stage 1 or, Gut Stage 1; Grade II



Secondary Outcome Measures:
  • Incidence of Epstein-Barr Virus (EBV) Reactivation [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    Number of participants who reactivated EBV. Patients had their plasma tested once weekly using the TaqMan polymerase chain reaction (PCR) for quantitative determination of EBV-DNA for 6 weeks. Plasma levels > 1000 copies per ml plasma were scored as positive.

  • Incidence of Rituximab Response to Reactivated EBV Without PTLD [ Time Frame: 100 days ] [ Designated as safety issue: Yes ]

    Participants who developed plasma EBV-DNA of >1000 copies/mL on any tests received rituximab.

    Incidence of Rituximab Response: Reactivated EBV participants whose plasma titers cleared after rituximab, without post-transplant lymphoproliferative disorder (PTLD).


  • Overall Survival (OS) [ Time Frame: At 2 years and 5 years ] [ Designated as safety issue: Yes ]
    Median OS in days. Survival was measured from the time of transplant to the time of death.

  • Pharmacodynamics of Visilizumab - Test 1 [ Time Frame: At 1 - 2 hours ] [ Designated as safety issue: No ]
    Mean Cmax (±SD)

  • Pharmacodynamics of Visilizumab - Test 2 [ Time Frame: Up to 205 hours ] [ Designated as safety issue: No ]
    Mean terminal half-life (±SD)


Enrollment: 8
Study Start Date: December 2007
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: First Study Stage: Study Treatment
Visilizumab, Tacrolimus and Methotrexate.
Drug: Visilizumab
3 mg/m^3, IV (in the vein) on day 0, prior to hematopoietic cell infusion (transplant).
Drug: Tacrolimus
0.02 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 4 after transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
Drug: Methotrexate
15 mg/m^2 intravenously (IV) on Day 1 after transplant; 10 mg/m^2 IV on Days 3, 6 and 11 after transplant.
Active Comparator: Second Study Stage: Standard Treatment
Second Stage: Antithymocyte-globulin (ATG), Tacrolimus and Methotrexate. The study was closed during first stage and did not proceed to the second stage comparison to ATG in combination with tacrolimus/methotrexate as originally planned.
Drug: Antithymocyte globulin (ATG)
1 mg/kg IV over 6 hours on Day 3 before transplant; 3.25 mg/kg IV over 4 hours on days 2 and 1 before transplant.
Other Name: Thymoglobulin-ATG
Drug: Tacrolimus
0.03 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 3 before transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
Drug: Methotrexate
15 mg/m^2 IV on Day 1 after transplant; 10 mg/m^2 IV on Days 3, 6 and 11 after transplant.

Detailed Description:

The protocol plan was a two stage, controlled, phase II study to assess safety and compare the grade of acute graft-versus-host disease (GVHD) with visilizumab, or Anti-thymocyte Globulin (ATG) in combination with tacrolimus + methotrexate in patients at high risk of GVHD after transplant from unrelated donors mismatched for 1-2 alleles of any type at human leukocyte antigen (HLA) A, B, C and DRB1.

The study design included two stages. The first stage of the trial was to enroll 15 patients on a single arm to be treated with "study treatment" (visilizumab, tacrolimus and methotrexate) to assess for treatment safety and exclude intolerable GVHD. The second stage of the trial was to include a random control group of patients treated with the current "standard treatment" (ATG, tacrolimus, and methotrexate) or "study treatment". The purpose of this comparison was to determine if the "study treatment" visilizumab causes less severe side effects and if it is more potent in reducing graft-versus-host disease symptoms than the "standard treatment".

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • One of the following diagnoses with histological confirmation by the Pathology Department at H. Lee Moffitt Cancer Center:
  • Acute Lymphocytic Leukemia (ALL) in complete remission 1 (CR1) with t(9:22) or t(4:11), or any ALL beyond CR1
  • Acute Myelogenous Leukemia (AML) with high risk cytogenetics in CR1 as defined by Bloomfield any AML beyond CR1
  • Myelodysplastic Syndrome (MDS) with International Prognostic Scoring System (IPSS) score > 1
  • Chronic myelomonocytic leukemia (CMML)
  • Chronic Myelogenous Leukemia (CML) with Imatinib-refractory chronic phase, or beyond chronic phase by morphology or cytogenetics
  • Myelofibrosis
  • Severe aplastic anemia
  • Chemosensitive Non-Hodgkin's lymphoma and Hodgkin's disease that are not candidate to autologous transplant due to prior autologous transplantation
  • Multiple Myeloma patient not candidate for autologous stem cell transplantation
  • Karnofsky performance status ≥ 70% (adult)
  • Normal organ and marrow function as defined below:
  • Hepatic: Total bilirubin must be less than or equal to 2mg/dL (Gilbert and other syndromes with increased indirect bilirubin are allowed); serum transaminases must be less than two times the upper limit of normal
  • Pulmonary: diffusing capacity of lung for carbon monoxide (DLCO) (corrected for Hgb), forced expiratory volume-one second (FEV1), forced vital capacity (FVC) must be greater than 50% predicted
  • Cardiac: Left ventricular ejection fraction at rest must be greater than 50%
  • Renal: Creatinine clearance (measured or calculated) must be equal or greater than 50 ml/min/1.73m^2

Exclusion Criteria:

  • Anti thymocyte globulin (ATG) or anti T cell therapy in prior 45 days
  • Splenectomized patients;
  • A positive pregnancy test administered to all females of childbearing potential prior to allogeneic stem cell transplant
  • Inability to comply with follow up as determined by the patient's physician
  • HIV-I/II infection prior to hematopoietic stem cell (HSC) transplantation, confirmed by nucleic acid test (NAT)
  • Uncontrolled bacterial or fungal infection
  • History of documented invasive aspergillosis or cytomegalovirus (CMV) pneumonia
  • Presence of any of the following comorbid conditions:
  • History of myocardial infarction
  • Congestive heart failure (even if symptomatically controlled)
  • Peripheral vascular disease (including intermittent claudication or history of bypass for arterial insufficiency)
  • Untreated thoracic or abdominal aneurysm (6cm or more)
  • History of any cerebrovascular accident including transient ischemic attacks
  • Dementia
  • History of peptic ulcer disease requiring treatment
  • Connective tissue/rheumatologic disorders
  • Diabetes unless being managed with dietary changes only
  • Hemiplegia/paraplegia
  • History of solid tumor excluding skin or cervical carcinoma after curative resection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00720629

Locations
United States, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States, 33612
Sponsors and Collaborators
H. Lee Moffitt Cancer Center and Research Institute
Investigators
Principal Investigator: Lia Perez, MD H. Lee Moffitt Cancer Center and Research Institute
  More Information

Additional Information:
No publications provided by H. Lee Moffitt Cancer Center and Research Institute

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier: NCT00720629     History of Changes
Other Study ID Numbers: MCC-15033, R01CA132197-06A2
Study First Received: July 21, 2008
Results First Received: May 1, 2014
Last Updated: July 10, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by H. Lee Moffitt Cancer Center and Research Institute:
graft versus host disease
GVHD
allogeneic transplant
GVHD prevention
unrelated donors
mismatched unrelated donors
hematological malignancies
Leukemia
Lymphoma
Myelodysplastic Syndrome
Myelofibrosis
Aplastic Anemia
Multiple Myeloma

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases
Antilymphocyte Serum
Methotrexate
Tacrolimus
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Immunosuppressive Agents
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Therapeutic Uses
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on August 26, 2014